In Brief: An Expanded Indication for Teplizumab (Tzield)
The Medical Letter on Drugs and Therapeutics · 22.06.2026 · 68 (1757) · 100-101
DOI: 10.58347/tml.2026.1757c ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 22.06.2026.
Abstract (Originalsprache)
The CD3-directed monoclonal antibody teplizumab (Tzield – Provention Bio), which was previously approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old with stage 2 type 1 diabetes, has now been approved for such use in children 1-7 years old.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). In Brief: An Expanded Indication for Teplizumab (Tzield). The Medical Letter on Drugs and Therapeutics, 68(1757), 100-101. https://doi.org/10.58347/tml.2026.1757c
Vancouver
In Brief: An Expanded Indication for Teplizumab (Tzield). The Medical Letter on Drugs and Therapeutics. 2026;68(1757):100-101. doi:10.58347/tml.2026.1757c
BibTeX
@article{euvimed2026,
title = {In Brief: An Expanded Indication for Teplizumab (Tzield)},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1757},
pages = {100--101},
doi = {10.58347/tml.2026.1757c}
}
EUVIMED